Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6245424 | 0.93 | ELANE (0.49) | RAB9ASMN1; SMN2NPC1MAPTELANE | |
| SCHEMBL6242996 | 0.92 | NPC1 (0.49) | RAB9ASMN1; SMN2NPC1MAPTCYP2C19 | |
| SCHEMBL6240974 | 0.86 | RAB9A (0.55) | RAB9ASMN1; SMN2NPC1MAPTCYP1A2 | |
| SCHEMBL6245063 | 0.83 | ALDH1A1 (0.47) | RAB9ASMN1; SMN2NPC1MAPTCYP1A2 | |
| SCHEMBL6802993 | 0.82 | RAB9A (0.52) | RAB9ASMN1; SMN2NPC1MAPTCYP1A2 | |
| SCHEMBL6178282 | 0.82 | ELANE (0.51) | ELANEALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL23460649 | 0.80 | ELANE (0.47) | ELANEALDH1A1KDM4E | |
| SCHEMBL6240894 | 0.78 | ELANE (0.51) | RAB9ASMN1; SMN2NPC1MAPTCYP1A2 | |
| SCHEMBL30765994 | 0.78 | ELANE (0.46) | ELANEALDH1A1KDM4E | |
| SCHEMBL7953847 | 0.78 | ELANE (0.53) | ELANECASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165234-A1 | Process for preparing pyrimidine compound | AJINOMOTO CO. INC (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1553090-A1 | PROCESS FOR PRODUCING PYRIMIDINE COMPOUND | Ajinomoto Co., Inc. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165234-A1 | Process for preparing pyrimidine compound | SERPINB1, CMA1, CTRC | RAB9A 2441/4885SMN1; SMN2 1017/4885NPC1 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.